We strive to be a global biopharma leader whose mission is
to develop innovative, life-changing medicine
MRSA (Methicillin-resistant Staphylococcus aureus)
- CG-549 met all efficacy endpoints in a U.S. Phase 2 clinical study for treatment of MRSA.
- 경구제제 유럽 임상 1상 시험 완료
Specific inhibition of the Fab l target, which is expressed only in the S. aureus family group
기존의 MRSA용 항생제들이 보이는 내성 및 다양한 부작용 없음
Showed superior non-clinical efficacy results when compared to top MRSA drugs Zyvox and Cubicin
U.S. Phase 2 clinical study results showed a 91 percent cure rate in MRSA patients within three days and a 100 percent cure for all MRSA patients within two weeks
- Enoyl-acyl carrier protein reductase is present in bacteria. This protein holds a vital role regarding bacterial fatty acid synthesis and is essential for survival.
- When Fab I is suppressed using CG-549, MRSA strains are selectively killed to treat infectious diseases without side effects to the human body.